Skip to content

Startup & venture capital news

Matchpoint Therapeutics raises USD 150m Series B

Nextech Invest and Norwest back oral treatments for autoimmune disease

By /

LinkedInX
Matchpoint Therapeutics: Matchpoint Therapeutics raises USD 150m Series B

Matchpoint Therapeutics announced a USD 150 million Series B on Wednesday 7 October 2026, co-led by Nextech Invest and Norwest. The US biotechnology company develops oral small-molecule treatments for autoimmune and inflammatory diseases. The financing supports its pipeline and planned clinical development of its lead candidate. Matchpoint's work focuses on drug design and the research needed to move potential treatments toward studies in people. The announcement is a development-stage investment story, linking specialist life-sciences investors with a company pursuing a defined therapeutic approach. The funding provides capital for the next stages of the programme described by the company and investors.

Keep reading

More Funding

All stories